NuCana announces grant of composition-of-matter patent for NUC-7738 in China

NuCana (NCNA) announced that the China National Intellectual Property Administration, CNIPA, has granted an important patent covering the composition of matter for NUC-7738. This patent is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of NUC-7738, NuCana’s novel anti-cancer agent currently being evaluated in a Phase 1/2 clinical study in combination with pembrolizumab for patients with PD-1 inhibitor refractory or resistant melanoma. Securing this patent represents an important milestone for NuCana, strengthening its long-term global intellectual property strategy, while supporting potential opportunities to address unmet needs for innovative cancer therapies in China.